Shares of WORK Medical Technology Group Ltd (NASDAQ: WOK) experienced extreme volatility after the company announced a strategic partnership with Shanghai Novabioplus Biotechnology Co. The stock surged 206% on Monday to close at $3.92, swinging between $0.19 and $4.09 during the session. However, early Tuesday premarket trading saw the shares drop 48% to $2.05, highlighting the speculative nature of the move.
AI and BioToken Collaboration
The Hangzhou-based medical device supplier revealed on April 13 that it had signed an agreement with Novabioplus to develop AI-driven models for protein and biological data. The collaboration will focus on four key initiatives: membrane protein design, antibody sequence optimization, enzyme molecule design, and peptide design. The companies aim to combine software models with laboratory data to design biological molecules for drug research.
WORK also introduced the concept of "BioTokens," digital assets representing biological data, as part of its broader push into AI, Web3, and healthcare data. However, the announcement lacked specific financial terms, customer details, or revenue projections, leaving investors with more questions than answers.
Financial Context and Risks
WORK reported 2025 revenue of $9.85 million and a net loss of $1.07 million, according to LSEG data cited by Reuters. The company, led by Chairman and CEO Shuang Wu, is a small-cap player trying to diversify beyond its core business of medical consumables, including face masks, endotracheal tubes, and breathing circuits.
The partnership announcement comes amid a broader trend of AI adoption in drug discovery. Major pharmaceutical companies like Eli Lilly have expanded collaborations with AI firms such as Insilico Medicine, with deals potentially worth billions. However, WORK faces stiff competition from established players like Certara, Schrödinger, and Recursion Pharmaceuticals, which already leverage AI for drug development.
Recent Strategic Shifts
The AI deal follows WORK's May 1 disclosure of a push into asset tokenization, healthcare real-world assets (RWAs), AI payments, and stablecoin-based cross-border settlement. RWAs involve digitizing physical or data assets on blockchains. This strategic pivot comes after the company executed a 1-for-100 reverse stock split in December to meet Nasdaq's minimum bid-price requirement, with approximately 1.22 million ordinary shares outstanding post-split.
While the market has responded positively to WORK's AI ambitions, the lack of concrete product launch timelines, financial commitments, or evidence that BioTokens will generate meaningful revenue leaves the stock vulnerable to sharp corrections. Investors are advised to monitor for further disclosures on deal terms and execution milestones.
